「ダパグリフロジン」の版間の差分

治験段階では血糖低下以外に、[[血圧]]低下、血清[[尿酸]]値低下、[[コレステロール]]プロファイルの改善、体重減少も有意に認められた。体重減少効果は主に体液の減少ではなくカロリーの減少に関連するものである<ref name="Yang, 2013">{{cite journal|last1=Yang|first1=Li|last2=Li|first2=Haiyan|last3=Li|first3=Hongmei|last4=Bui|first4=Anh|last5=Chang|first5=Ming|last6=Liu|first6=Xiaoni|last7=Kasichayanula|first7=Sreeneeranj|last8=Griffen|first8=Steven C.|last9=Lacreta|first9=Frank P.|year=2013|title=Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects|journal=Clinical Therapeutics|volume=35|issue=8|pages=1211–1222.e2|doi=10.1016/J.Clinthera.2013.06.017|pmid=23910664|last10=Boulton|first10=David W.}}</ref><ref name="Plosker, 2012">{{cite journal|last1=Plosker|first1=Greg L.|year=2012|title=Dapagliflozin|journal=Drugs|volume=72|issue=17|pages=2289–2312|doi=10.2165/11209910-000000000-00000|pmid=23170914}}</ref>。

 

<ref>{{cite journal | vauthors = Toru Kondo, Ulrik M Mogensen, Atefeh Talebi, Samvel B Gasparyan, Ross T Campbell, Kieran F Docherty, Rudolf A de Boer, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Marc S Sabatine, Olof Bengtsson, Mikaela Sjöstrand, Muthiah Vaduganathan, Scott D Solomon, Pardeep S Jhund, John J V McMurray | title = Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial | journal = J Am Coll Cardiol. | volume = 83 | issue = 20 | pages = 1973-1986. | date = May 2024 | pmid = 38537918 | doi = 10.1016/j.jacc.2024.03.385. }}</ref>。

<ref>{{cite journal | vauthors = Cox ZL, Collins SP, Hernandez GA, et al. | title = Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. | journal = J Am Coll Cardiol. | volume = 83 | issue = 14 | pages = 1295-1306. | date = April 2024 | pmid = 38569758 | doi = 10.1016/j.jacc.2024.02.009. }}</ref>。